Login to Your Account



Earnings Roundup


Thursday, November 8, 2012

• Vivus Inc., of Mountain View, Calif., reported net product revenues of $41,000 from prescriptions of newly approved obesity drug Qsymia (phentermine/topiramate) shipped from certified pharmacies to patients. The drug, approved in July, was made available starting Sept. 17.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription